BostonGene, Daiichi Sankyo Partner on AI

- Daiichi Sankyo specializes in a type of cancer therapy called antibody-drug conjugates (ADCs), which are designed to deliver potent drugs directly to cancer cells while minimizing harm to healthy tissue. The collaboration will leverage BostonGene's AI to better identify which patients are most likely to benefit from these targeted therapies. - BostonGene's AI platform creates a detailed molecular profile of a patient's cancer by integrating multiple types of data, including genomics (DNA), transcriptomics (RNA), and digital pathology images. This multi-modal approach generates a "digital twin" of the tumor to identify biological signatures that can predict a drug's effectiveness. - Founded in 2015, BostonGene has raised hundreds of millions of dollars from investors to build its AI-driven platform, highlighting the significant capital required to merge advanced computing with biological research. - This partnership showcases two distinct career paths: computational biologists at BostonGene analyze large biological datasets and build predictive models, while clinical research professionals at Daiichi Sankyo design and manage the human trials that test the drugs developed from these computational insights. - A career in computational biology typically requires a mix of advanced biology and computer science skills, including programming in languages like Python and R, with many professionals holding a master's degree or a Ph.D. - The Global Head of Precision Medicine at Daiichi Sankyo, Dale Shuster, previously identified the molecular genetics of a fatal immunodeficiency in Holstein cattle and developed the diagnostic test that eradicated the disease, showing how precision medicine skills can apply to different areas of biology. - A primary goal of using AI in this context is to improve the design of clinical trials by better selecting patients whose tumor biology makes them most likely to respond to the investigational drug. This can help make drug development faster and more successful. - BostonGene's platform has been developed and validated through collaborations with major research institutions, including Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.